Horbar Jeffrey D, Carpenter Joseph H, Buzas Jeffrey, Soll Roger F, Suresh Gautham, Bracken Michael B, Leviton Laura C, Plsek Paul E, Sinclair John C
Vermont Oxford Network, 33 Kilburn Street, Burlington, VT 05401, USA.
BMJ. 2004 Oct 30;329(7473):1004. doi: 10.1136/bmj.329.7473.1004.
To test a multifaceted collaborative quality improvement intervention designed to promote evidence based surfactant treatment for preterm infants of 23-29 weeks' gestation.
Cluster randomised controlled trial.
114 neonatal intensive care units (which treated 6039 infants of 23-29 weeks gestation born in 2001).
Process of care measures: proportion of infants receiving first surfactant in the delivery room, proportion receiving first surfactant more than two hours after birth, and median time from birth to first dose of surfactant. Clinical outcomes: death before discharge home, and pneumothorax.
Multifaceted collaborative quality improvement advice including audit and feedback, evidence reviews, an interactive training workshop, and ongoing faculty support via conference calls and email.
Compared with those in control hospitals, infants in intervention hospitals were more likely to receive surfactant in the delivery room (adjusted odds ratio 5.38 (95% confidence interval 2.84 to 10.20)), were less likely to receive the first dose more than two hours after birth (adjusted odds ratio 0.35 (0.24 to 0.53)), and received the first dose of surfactant sooner after birth (median of 21 minutes v 78 minutes, P < 0.001). The intervention effect on timing of surfactant was larger for infants born in the participating hospitals than for infants transferred to a participating hospital after birth. There were no significant differences in mortality or pneumothorax.
A multifaceted intervention including audit and feedback, evidence reviews, quality improvement training, and follow up support changed the behaviour of health professionals and promoted evidence based practice.
测试一项多方面协作的质量改进干预措施,该措施旨在促进对妊娠23 - 29周的早产儿进行基于证据的表面活性剂治疗。
整群随机对照试验。
114个新生儿重症监护病房(收治了2001年出生的6039名妊娠23 - 29周的婴儿)。
护理过程指标:在产房接受首次表面活性剂治疗的婴儿比例、出生后两小时以上接受首次表面活性剂治疗的比例,以及从出生到首次给予表面活性剂的中位时间。临床结局:出院前死亡和气胸。
多方面协作的质量改进建议,包括审核与反馈、证据综述、互动培训工作坊,以及通过电话会议和电子邮件提供持续的专业支持。
与对照医院的婴儿相比,干预医院的婴儿更有可能在产房接受表面活性剂治疗(调整后的优势比为5.38(95%置信区间为2.84至10.20)),出生后两小时以上接受首剂治疗的可能性更小(调整后的优势比为0.35(0.24至0.53)),并且出生后更快接受首剂表面活性剂治疗(中位时间为21分钟对78分钟,P < 0.001)。参与医院出生的婴儿在表面活性剂给药时间上的干预效果大于出生后转入参与医院的婴儿。在死亡率和气胸方面没有显著差异。
一项包括审核与反馈、证据综述、质量改进培训和后续支持的多方面干预措施改变了医护人员的行为,并促进了基于证据的实践。